Figure 6.

Anlotinib decreased tumor angiogenesis and cell proliferation. IHC analysis of CD31, EGFR, MVD, and Ki‐67 expression of representative tumor sections in each group. ×400. Group 1, vehicle control (DD‐H2O); Group 2, low‐dose anlotinib (1.5 mg/kg per day); Group 3, high‐dose anlotinib (3.0 mg/kg per day); Group 4, epirubicin (2.5 mg/kg per week); Group 5, low‐dose anlotinib (1.5 mg/kg per day) and epirubicin (2.5 mg/kg per week); Group 6, high‐dose anlotinib (3.0 mg/kg per day) and epirubicin (2.5 mg/kg per week)